Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11600616 | 1.00 | MCL1 (0.53) | MCL1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL9887744 | 0.84 | KMT2A (0.55) | MCL1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL20746874 | 0.81 | KMT2A (0.52) | MCL1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL9565143 | 0.81 | KMT2A (0.52) | MCL1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL27852170 | 0.80 | MCL1 (0.57) | MCL1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL9868488 | 0.80 | MCL1 (0.57) | MCL1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL21807358 | 0.80 | MCL1 (0.57) | MCL1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL21795440 | 0.79 | KMT2A (0.50) | MCL1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL21807395 | 0.79 | MCL1 (0.47) | MCL1KMT2ADAOALDH1A1MAPT | |
| SCHEMBL2423816 | 0.79 | MCL1 (0.47) | MCL1KMT2ADAOALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250120948-A1 | Small Molecules G(alpha)I2 Inhibitors and Combination With Anticancer Drugs and Use Thereof | CLARK ATLANTA UNIVERSITY | 2025-04-17 | — | — | US | disclosed |
| WO-2024249642-A1 | EGFR INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120948-A1 | Small Molecules G(alpha)I2 Inhibitors and Combination With Anticancer Drugs and Use Thereof | GDI2, GNAI2, GNAI3 | MCL1 1450/4885KMT2A 4001/4885DAO 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.